On September 7, 2022 Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) ("Cipla") reported that it has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (US FDA) (Press release, Cipla, SEP 7, 2022, View Source [SID1234619216]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cipla’s Lenalidomide Capsules are the AB-rated therapeutic equivalent generic version of Bristol Myers Squibb’s (Celgene) Revlimid (Lenalidomide) Capsules.

Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as; Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma. Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings.

Lenalidomide capsules are not to be used by pregnant women. It is not known if lenalidomide is safe and effective for children. Lenalidomide Capsules should not be used to treat people with chronic lymphocytic leukemia (CLL) outside of a controlled clinical trial.

According to IQVIA (IMS Health), Revlimid (Lenalidomide) Capsules had US sales of approximately $ 2.58 billion for the 12-month period ending June 2022.

The product will be available for shipping soon.